Olanzapine‐fluoxetine combination has some benefit, but placebo effect and adverse events high

Publisher: John Wiley & Sons Inc

E-ISSN: 1556-7567|17|4|1-7

ISSN: 1527-8395

Source: THE BROWN UNIVERSITY CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY UPDATE, Vol.17, Iss.4, 2015-04, pp. : 1-7

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Adolescents and children diagnosed with bipolar disorder (BP) have a significantly reduced quality of life, including greater risk of suicidal behavior. Rapid intervention is critical, but unfortunately pharmacological treatments are challenging, with antidepressants sometimes causing manic symptoms. While there are medications effective in treating mania, the depressive phase is more difficult to treat. Only three medications are approved by the Food and Drug Administration (FDA) for the acute treatment of bipolar depression in adults: quetiapine, lurasidone, and olanzapine/fluoxetine combination (OFC).